Indaptus Therapeutics Inc
INDP
NASDAQ
Biotechnology
$1.07
USD
+0.01 (+0.94%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $120.04M
Volume 130.8K
Revenue
$0
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
$-18.86M
TTM
-19.7%
YoY
Operating Cash Flow
$-16.79M
TTM
-25.0%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 1.8 | 2.3 | 1.1 | 5.3 | 1.7 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 4.6 | 4.5 | 2.6 | 8.2 | 2.2 |
Operating Income | -4.6 | -4.5 | -2.6 | -8.2 | -2.2 |
EBITDA | -4.6 | -4.5 | -2.6 | -8.2 | -2.2 |
Other Income / Expense | 0.0 | -0.8 | -0.3 | 0.0 | -0.4 |
Total Other Income / Expense | 0.0 | -0.8 | -0.3 | 0.0 | -0.4 |
Income Before Income Taxes | -4.5 | -5.2 | -3.0 | -8.1 | -2.5 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -4.5 | -5.2 | -3.0 | -8.1 | -2.5 |
Consolidated Net Income / Loss | -4.5 | -5.2 | -3.0 | -8.1 | -2.5 |
Net Income Attributable to Common Shareholders | -4.5 | -5.2 | -3.0 | -8.1 | -2.5 |
Basic EPS | -$9.11 | -$9.09 | -$2.98 | -$4.52 | -$0.23 |
Diluted EPS | -$9.11 | -$9.09 | -$2.98 | -$4.52 | -$0.23 |
Basic Shares Outstanding | 0.5M | 0.6M | 1.0M | 1.8M | 11.0M |
Diluted Shares Outstanding | 0.5M | 0.6M | 1.0M | 1.8M | 11.0M |